This page shows the publications co-authored by Nahel Elias and Meghan Sise.
Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation. Artif Organs. 2019 Sep; 43(9):913-920.
Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int. 2021 12; 34(12):2562-2569.
Influence of donor and recipient hepatitis B virus infection on long-term outcomes after kidney transplantation. Clin Transplant. 2021 12; 35(12):e14466.
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol. 2020 11; 31(11):2678-2687.
Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep. 2020 Apr; 5(4):459-467.
Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodial Int. 2018 04; 22 Suppl 1:S71-S80.
Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant. 2022 Feb; 22(2):599-609.
Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020 06; 20(6):1619-1628.
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016; 11(7):e0158431.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.